Online inquiry

IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3018MR)

This product GTTS-WQ3018MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA4&ITGB7&ITGAE gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000885.6; NM_000889.3; NM_002208.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3676; 3695; 3682
UniProt ID P13612; P26010; P38570
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3018MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ173MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ10855MR IVTScrip™ mRNA-Anti-FOLR1, M9346A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M9346A
GTTS-WQ9800MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ12015MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-302
GTTS-WQ7446MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ8515MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ8244MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HLX10
GTTS-WQ9357MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW